Redeye AB

Redeye congratulates Spago Nanomedical AB on the successful redemption of TO12 warrants, which achieved a subscription rate of 97%.

Redeye initiates coverage of AcouSort, a Swedish medtech company aiming to introduce its unique acoustofluidic technology in the automation of the sample preparation process in diagnostics, analytics, and cell therapy manufacturing. Our base case suggests a significant upside potential in the share, and we argue that the main catalysts to close the valuation gap are further progress with its partners and accelerating sales from OEM components. https://lnkd.in/dgeGpF4V

Redeye hosts a SaaS event on June 5, 08:40-15:25. We have invited several interesting companies in the sector to present, followed by a Q&A session. For more information, visit the event page: https://lnkd.in/dDsrszpc Schedule: 08.40 Introduction by Redeye Analyst 08.50 Admicom: Petri Kairinen, CEO 09.10 Modelon: Magnus Gäfvert, CEO 09.30 Safeture: Magnus Hultman, CEO 09.50 Sleep Cycle: Erik Jivmark, CEO 10.10 Artificial Solutions: Per Ottosson, CEO 10.30 Break 10.45 QPR Software Plc: Mervi Kerkelä-Hiltunen, CFO 11.05 24SevenOffice: Eirik Aalvik Stranden, CEO 11.25 Vertiseit AB: Johan Lind, CEO 11.45 QBank DAM: Anna Gomes, CEO 12.05 Lunch 13.10 Carasent ASA: Daniel Öhman, CEO 13.30 Oneflow: Anders Hamnes, CEO 13.50 Kontigo Care: Ulrika Giers, CEO 14.10 Break 14.25 SmartCraft: Gustav Line, CEO 14.45 Lime Technologies: Nils Olsson, CEO 15.05 Formpipe: Magnus Svenningson, CEO

Redeye provides its Q1 2024 sector update for Swedish serial acquirers. We discuss recent news flow for the companies we cover and how valuations have returned to more optimistic levels since the fall of 2023. Inspired by a recent InPractise interview, we examine how serial acquirers in our index have handled purchase price allocation in the last 10 years. Lastly, we review Brad Jacobs’ book on how to make a few billion dollars. Read the full report: https://lnkd.in/dN-fKVpD

Redeye is proud to act as Sole Manager and Bookrunner in Vertiseit's directed issue and placement of secondary shares, of in total, SEK 119 million. The transaction was directed to, among others, Andra AP-fonden (AP2), NEA Partners Public Value, Bonnier Capital , Aktiebolag Grenspecialisten , ALCUR FONDER AB and Nordea Fonder. Vertiseit AB is a leading Digital In-store company offering the In-store Experience Management (IXM) SaaS platforms Grassfish and Dise. The platforms help global brands and leading retailers strengthen the customer experience by offering seamless customer journeys through connecting the physical and digital meeting.

On Thursday, May 30, we will be joined by a number of interesting growth companies, investors, and experts to explore investment themes like the data-driven world, new age consumer, green revolution, and more. Limited in-person spots are available for invited guests. Experience interactive 1-2 minute company pitches and insightful 18-minute Q&A sessions. Dive deep into different investment themes with our clustered program. A personal invite is needed to attend this event. If you wish to be invited, please contact: events@redeye.se   Discover how we analyze opportunities using industry expertise and unique quality rating methods. Connect with industry leaders and experts, engaging in conversations to elevate your investment strategies for the future.   Throughout the day, there will be an opportunity to socialize with investors, company representatives, and Redeye employees, ending with an exclusive after-work gathering. For more information, please visit the event page: https://lnkd.in/dKDM-VfH

InDex Pharmaceuticals AB has entered into an agreement with the shareholders of Flerie Invest AB to acquire all shares in Flerie through an issue in kind. The transaction values Flerie at approximately SEK 3,073 million and InDex Pharmaceuticals at approximately SEK 269 million, making Flerie a wholly-owned subsidiary of InDex Pharmaceuticals. As a result of the transaction, InDex Pharmaceuticals will change its name to Flerie AB.   Redeye is proud to act as financial advisor in connection with the transaction and would like to thank InDex Pharmaceuticals for the vote of confidence.

Redeye provides its Q1 2024 sector update for the Nordic IT Consulting space. We discuss IT Consulting companies in our coverage universe, other IT Consulting businesses we find interesting, their operational performance, and valuations. Read the full report: https://lnkd.in/dn3Ar8Cf

On May 23, Redeye hosts its second Theme Diabetes event. Interesting companies in different areas within the theme will share their equity story, project status, and triggers ahead. Visit the event page for information on how to to attend: https://lnkd.in/dKidRU2z This is a unique opportunity for investors interested in this space to learn more, hopefully generating new investment ideas.   Following the presentations, Redeye’s analysts will hold Q&A sessions where questions are open to the audience. Schedule: 09.00 Intro by Redeye – Filip Einarsson, Equity Analyst 09.10 NextCell Pharma AB – Mathias Svahn, CEO 09.30 PILA PHARMA – Gustav Hanghøj Gram, CEO 09.50 Lipigon Pharmaceuticals AB – Stefan K. Nilsson, CEO 10.10 Pause 10.30 Nanexa AB – David Westberg, CEO 10.50 Optomed Plc – Juho Himberg, CEO 11.10 Nanologica AB – Andreas Bhagwani, CEO 11.30 The End 

Redeye initiates coverage of Navigo Invest AB (publ), a holding company of strategic acquirer platforms. We judge the company’s recent divestments and acquisitions to have obscured underlying value, as reported financials do not yet fully reflect underlying earnings power. We believe all subsidiaries being fully consolidated and seeing growth from a recovering economy could drive share price appreciation in 2024e–2025e. Read the full report: https://lnkd.in/daYTU9Bb